According to Mallinckrodt Pharmaceuticals 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.00233125. At the end of 2023 the company had a P/S ratio of 0.0080.
Year | P/S ratio | Change |
---|---|---|
2023 | 0.0080 | -84.97% |
2022 | 0.0533 | 1012.11% |
2021 | 0.0048 | -37.59% |
2020 | 0.0077 | -91.72% |
2019 | 0.0928 | -81.11% |
2018 | 0.4914 | -18.72% |
2017 | 0.6046 | -58.19% |
2016 | 1.45 | -36.78% |
2015 | 2.29 | -43.03% |
2014 | 4.02 | 197.43% |
2013 | 1.35 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
![]() Johnson & Johnson JNJ | 3.91 | 167,478.34% | ๐บ๐ธ USA |
![]() General Electric GE | 2.45 | 105,181.29% | ๐บ๐ธ USA |
![]() Zogenix ZGNX | N/A | N/A | ๐บ๐ธ USA |
![]() Teva Pharmaceutical Industries TEVA | 1.21 | 51,997.80% | ๐ฎ๐ฑ Israel |